AZIYO BIOLOGICS(US:AZYO)2025-05-13 20:50Financial Performance - Net sales for Q1 2025 were $6,030,000, a decrease of 9.9% compared to $6,694,000 in Q1 2024[29] - Gross profit for Q1 2025 was $2,457,000, down from $2,843,000 in Q1 2024, reflecting a gross margin of 40.7%[29] - The net loss for Q1 2025 was $3,933,000, significantly improved from a net loss of $17,994,000 in Q1 2024[29] - The company reported a loss from operations of $7,922,000 for Q1 2025, slightly improved from a loss of $8,479,000 in Q1 2024[29] - For the three months ended March 31, 2025, the company reported a net loss of $3.93 million, compared to a net loss of $17.99 million for the same period in 2024[135] - The company’s segment gross profit for the three months ended March 31, 2025, was $3.31 million, down from $3.69 million in the same period of 2024[138][139] - Loss before provision for income taxes improved to $(3,925,000) in Q1 2025 from $(17,986,000) in Q1 2024, representing a reduction of 78.2%[140] Assets and Liabilities - Total current assets increased to $30,017,000 as of March 31, 2025, compared to $26,172,000 as of December 31, 2024, representing a 10.8% increase[27] - Total liabilities decreased to $75,756,000 as of March 31, 2025, down from $82,387,000 as of December 31, 2024, a reduction of 8.1%[27] - Long-term debt as of March 31, 2025, was $21,762,000, a decrease from $22,603,000 as of December 31, 2024[105] - The company had cash of approximately $17.4 million as of March 31, 2025, with an accumulated deficit of $233.5 million[183] - As of March 31, 2025, the company had $24.3 million of total indebtedness, including $23.8 million under the SWK Loan Facility[197] Cash Flow and Financing - The Company used $8.9 million of cash in operating activities during the same period and expects continued cash outflows throughout 2025[44] - For the three months ended March 31, 2025, net cash used in operating activities was $8.9 million, an increase from $2.6 million in the same period in 2024, primarily due to higher trade obligations and FiberCel settlement payments of $3.0 million[193] - The company reported net cash provided by financing activities of $13.3 million for the three months ended March 31, 2025, compared to cash used of $4.1 million in the same period in 2024, mainly due to the 2025 Registered Offering[196] - The company raised approximately $15.0 million in gross proceeds from a registered direct offering on February 4, 2025, selling 5,520,000 shares of Class A common stock[110] - The company raised $2.2 million in outstanding royalty obligations to Ligand by issuing 1,105,528 shares of Class A common stock[210] Research and Development - Research and development expenses for Q1 2025 were $905,000, down from $1,172,000 in Q1 2024, indicating a 22.8% reduction[29] - Research and development costs are expensed as incurred, primarily consisting of salaries, outside services, and supplies[77] - Research and development expenses primarily focus on expanding the EluPro product line and developing new DEB products[163] Litigation and Contingencies - The company has settled liabilities in 52 cases of the FiberCel Litigation for a total cash outlay of $17.5 million, with an estimated probable loss of $14.3 million recorded for the remaining cases as of March 31, 2025[126] - As of March 31, 2025, there were 58 active lawsuits related to FiberCel, with 18 settlements reached but not yet paid[122] - The company has a contingent liability of $3.6 million related to the VBM Litigation as of March 31, 2025[129] - The company has recorded insurance receivables of $3.9 million related to litigation costs as of March 31, 2025[132] - Litigation costs increased to $2.6 million in Q1 2025 from $1.8 million in Q1 2024, primarily due to the lack of insurance coverage for certain litigation costs[174] Going Concern and Capital Needs - The Company has substantial doubt about its ability to continue as a going concern within one year from the issuance of the financial statements due to liquidity issues[45] - There is substantial doubt about the company's ability to continue as a going concern within one year after the issuance of the financial statements due to liquidity uncertainties[190] - The company may need additional funds sooner than anticipated, leading to potential dilution of ownership interests if additional capital is raised through equity or convertible debt securities[214] Inventory and Revenue Recognition - The Company evaluates its inventory for excess quantities and obsolescence, adjusting carrying values as necessary[60] - The Company recognizes revenue when control of products transfers to customers, primarily upon shipment or delivery[70] - A portion of the Company's product revenue comes from consigned inventory, with revenue recognized when the product is used or implanted[71] - As of March 31, 2025, the Company had total inventory of $4.286 million, an increase from $3.911 million as of December 31, 2024[98] Stock and Compensation - The weighted average common shares outstanding for diluted earnings per share increased to 42,913,111 in Q1 2025 from 23,912,326 in Q1 2024[29] - The Company reported a total stock-based compensation expense of $1.211 million for the three months ended March 31, 2025, a decrease of 44.8% compared to $2.197 million for the same period in 2024[97] - The Company had 3,204,215 stock options outstanding as of March 31, 2025, with a weighted average exercise price of $5.23 and an aggregate intrinsic value of $22,000[88] - The Company had 1,342,766 unvested restricted stock units (RSUs) as of March 31, 2025, with a weighted average grant date fair value of $3.49[92] - The Company had approximately $2.7 million of total unrecognized compensation expense related to unvested stock options expected to be recognized over a weighted-average period of 1.7 years[88] - The Company had $3.9 million of unrecognized compensation costs related to RSUs expected to be recognized over a weighted average period of 1.8 years[93] Market Risks and Accounting Policies - The company is exposed to various market risks, including interest rate risk, foreign currency risk, and credit risk, which could impact financial performance[220][221][223] - A hypothetical 10% relative change in interest rates on variable rate indebtedness as of March 31, 2025, would not have had a material effect on the financial statements[221] - The company has not experienced material changes in critical accounting policies and estimates during the three months ended March 31, 2025, other than those outlined in Note 2[215] - The company has elected to take advantage of the JOBS Act exemptions, allowing for an extended transition period for adopting new accounting standards[218] - The company will remain an emerging growth company until annual gross revenues reach $1.235 billion or more, or until other specified conditions are met[219] Operational Developments - The Company completed the sale of its Orthobiologics segment to Berkeley Biologics for approximately $14.6 million, with potential earn-out payments of up to $20 million based on future sales[41] - The Company recognized a gain of $6.0 million from the sale of the Orthobiologics Business in Q4 2023 and an additional gain of $0.2 million in Q2 2024[41] - The Company executed a new lease for 26,598 square feet with monthly payments of approximately $75,000, expiring in January 2036[63] - EluPro, the only drug-eluting biomatrix in the U.S. implantable electronic device protection market, was cleared for marketing by the FDA in June 2024[153] - The company expects to commence operations in a new facility in Gaithersburg, Maryland, in Q2 2025, aiming to internally produce components of EluPro by Q4 2025[152] - The company plans to expand its drug-eluting biomatrix (DEB) offerings beyond EluPro to address unmet clinical needs in breast reconstruction and neurostimulation[147][148] - SimpliDerm is marketed through a distribution agreement with Tiger Aesthetics Medical, providing access to approximately 50 sales representatives[150]